4 completed, 4 terminated. 8 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 8 | Completed 4, Terminated 4 |
| Phase 2 | 1 | Terminated 1 |
Follow difelikefalin: new trials by email Literature Review of difelikefalin trials Research Report on difelikefalin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Efficacy and Safety of Oral Difelikefalin for Moderate to Severe Pruritus in Subjects With Notalgia Paresthetica difelikefalin 2.0 mg tablets, difelikefalin 1.0 mg tablets, difelikefalin 0.25 mg tablets - Pruritus, Notalgia Paresthetica | Phase 2 / Phase 3 | Terminated | Cara Therapeutics, Inc. | 214 | 2023-08-01 | 2024-06-21 |
| Phase 3 Study of Difelikefalin in Haemodialysis Chinese Adult Subjects With Moderate-to-Severe Pruritus Difelikefalin Injection, Placebo Injection - Uremic Pruritus | Phase 3 | Completed | Vifor Fresenius Medical Care Renal Pharma | 260 | 2023-05-18 | 2025-09-12 |
| CR845-310302: A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus Difelikefalin 1 mg Oral Tablet, Placebo Oral Tablet - Chronic Kidney Diseases, Pruritus | Phase 3 | Terminated | Cara Therapeutics, Inc. | 105 | 2022-08-26 | 2024-05-07 |
| Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis difelikefalin 0.25 mg, difelikefalin 0.5 mg, TCS Cream - Pruritus, Atopic Dermatitis | Phase 3 | Terminated | Cara Therapeutics, Inc. | 287 | 2022-08-16 | 2024-02-22 |
| A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus Difelikefalin 1 mg Oral Tablet, Placebo Oral Tablet - Chronic Kidney Diseases, Pruritus | Phase 3 | Terminated | Cara Therapeutics, Inc. | 286 | 2022-05-17 | 2024-05-07 |
| CR845-CLIN3105: A Study to Evaluate the Safety and Effectiveness of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus CR845 0.5 mcg/kg - Uremic Pruritus | Phase 3 | Completed | Cara Therapeutics, Inc. | 222 | 2019-05-06 | 2021-10-15 |
| CR845-CLIN3103: A Global Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus CR845 0.5 mcg/kg, Placebo - Uremic Pruritus | Phase 3 | Completed | Cara Therapeutics, Inc. | 473 | 2018-07-17 | 2022-04-26 |
| A Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus (KALM-1) CR845 0.5 mcg/kg, Placebo - Uremic Pruritus | Phase 3 | Completed | Cara Therapeutics, Inc. | 378 | 2018-02-20 | 2022-04-26 |
Pruritus (7) · Kidney Failure, Chronic (5) · Renal Insufficiency, Chronic (5) · Dermatitis, Atopic (1) · Eczema (1)
Cara Therapeutics, Inc. (7) · Vifor Fresenius Medical Care Renal Pharma (1)
United States (7) · Poland (4) · Germany (3) · Hungary (3) · Australia (2) · Canada (2) · Czechia (2) · South Korea (2) · Spain (2) · Argentina (1) · Brazil (1) · Bulgaria (1) · China (1) · Italy (1) · Mexico (1)
PMID 36039153, PMID 37968132, PMID 39037824, PMID 33283264, PMID 36016762, PMID 31702883, PMID 36185706, PMID 37927032, PMID 38196014, PMID 41686509